Liver Cancer (Hepatocellular Carcinoma): Guide to Care & Treatment

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, which means the cancer originates directly within the liver tissue rather than spreading from another site in the body. The liver is the largest internal organ, functioning as a sophisticated processing plant that neutralises toxins, manufactures essential blood-clotting proteins, produces bile for digestion, and stores glycogen for energy. Within this organ, hepatocytes constitute approximately 80% of the cellular mass, carrying out the majority of these daily metabolic tasks. When cellular DNA within hepatocytes acquires mutations over time, these cells can begin dividing uncontrollably, forming one or more malignant tumours.

Unlike many other internal cancers that appear de novo in otherwise healthy organs, HCC has a unique natural history: in approximately 80% to 90% of cases, it develops within a liver already compromised by chronic injury, progressive fibrosis, and cirrhosis. Cirrhosis is characterised by the replacement of healthy, pliable liver architecture with dense, non-functional scar tissue and regenerative nodules. This ongoing cycle of long-standing cellular death, architectural distortion, and compensatory cellular regeneration creates an environment vulnerable to the accumulation of genetic alterations, eventually culminating in malignant transformation.

Because the liver possesses substantial functional redundancy, tumours can often grow silently without causing noticeable disruption to day-to-day metabolic health in their initial stages. Consequently, hepatocellular carcinoma is biologically heterogeneous; tumours can present as a single discrete mass, as multiple distinct nodules distributed across different liver segments, or, less commonly, as a diffuse, infiltrative process that permeates the liver parenchyma. Successfully treating the condition requires addressing both the oncological threat of the cancer and the physiological limits imposed by the patient's underlying liver tissue.

For you and your family, a diagnosis of hepatocellular carcinoma means that your medical care will be coordinated by a team of diverse specialists rather than a single doctor. This multidisciplinary team typically includes hepatologists (liver specialists), surgical oncologists, transplant surgeons, interventional radiologists, medical oncologists, and dedicated specialist nurses. Every decision made will consider two parallel aspects of your health: the exact location and size of the tumour, and the current health and resilience of the remaining non-cancerous portions of your liver.

In daily life, this means your treatment plan will be highly personalised. What is appropriate for one patient with HCC might be unsafe for another, simply because their underlying liver reserves differ. You will likely undergo close monitoring that includes blood tests, nutritional reviews, and regular imaging. While hearing that you have liver cancer is distressing, modern medicine provides a broader array of targeted treatments, sophisticated radiological procedures, and novel immunotherapies than ever before, focused on extending your life while maintaining your comfort and daily independence.

In its earliest stages, hepatocellular carcinoma is frequently asymptomatic. Because the liver lacks sensory pain receptors within its inner tissue—only the outer fibrous capsule (Glisson's capsule) contains nerve endings sensitive to stretch—a small tumour growing within the liver parenchyma rarely generates pain or physical sensations. Most early-stage tumours are discovered incidentally during routine medical check-ups or through scheduled surveillance programmes for individuals already known to have cirrhosis or chronic hepatitis.

As the tumour expands, or as background liver function deteriorates, noticeable symptoms may begin to emerge. Patients frequently report non-specific systemic signs, such as progressive, uncharacteristic fatigue, unintended weight loss, and a persistent loss of appetite (anorexia). Some individuals experience early satiety, feeling full after eating only small amounts of food, which can occur when an enlarged liver presses directly against the stomach. When pain does develop, it is typically felt as a dull, persistent ache in the right upper quadrant of the abdomen or right shoulder tip (referred pain mediated by the phrenic nerve).

Other symptoms often reflect worsening liver failure or increased pressure within the portal venous system (portal hypertension). These signs include jaundice—a yellowish discolouration of the skin and the whites of the eyes caused by a build-up of bilirubin—accompanied by dark urine and pale, clay-coloured stools. Patients may also develop swelling in the legs and ankles (peripheral oedema) or a progressive accumulation of fluid in the abdominal cavity, a condition known as ascites. More serious complications requiring immediate emergency attention include confusion, severe lethargy, or altered sleep patterns (hepatic encephalopathy), as well as vomiting blood or passing black, tarry stools, which can signal bleeding from enlarged veins in the oesophagus or stomach (oesophageal varices).

At the molecular level, hepatocellular carcinoma is caused by cumulative DNA damage within hepatocytes that disrupts normal controls over cell division, growth, and programmed cell death (apoptosis). Over time, chronic injury to liver tissue causes continuous cycles of cell destruction and regeneration. Each time a hepatocyte divides to replace lost tissue, its DNA must be replicated; in an inflamed, oxidative environment, the likelihood of uncorrected genetic copying errors rises substantially. Key genetic alterations often involve mutations in the promoter region of the TERT gene, which maintains protective caps on chromosomes, as well as alterations in tumour suppressor pathways such as TP53 and cell-signalling networks like the Wnt/beta-catenin pathway.

While the underlying cellular mechanism involves genetic and epigenetic instability, the external triggers driving this continuous inflammation are well documented. Chronic viral hepatitis infections represent a major global driver. Hepatitis B virus (HBV) is a DNA virus capable of integrating directly into the host genome, which can induce oncogenic mutations even in the absence of established cirrhosis. Hepatitis C virus (HCV), by contrast, is an RNA virus that causes chronic, smouldering inflammation and progressive fibrosis over several decades, almost exclusively triggering HCC once cirrhosis has become established. In both instances, long-term viral replication provokes immune-mediated destruction of liver tissue, providing the chronic inflammatory substrate needed for malignant progression.

The single greatest risk factor for developing hepatocellular carcinoma is cirrhosis of the liver, regardless of its underlying cause. Roughly 80% or more of individuals diagnosed with HCC have pre-existing cirrhosis. Beyond chronic viral hepatitis B and C infections, heavy and sustained alcohol consumption is a primary risk factor, as the toxic by-products of alcohol metabolism cause chronic steatohepatitis, progressive fibrosis, and eventual cirrhotic transformation. In recent years, metabolic dysfunction-associated steatohepatitis (MASH)—arising from fatty liver disease linked to insulin resistance, obesity, hypertension, and hyperlipidaemia—has become one of the fastest-growing causes of HCC in high-income nations.

Environmental and inherited conditions also contribute to overall risk. Exposure to aflatoxins—carcinogenic toxins produced by Aspergillus fungi that can contaminate improperly stored grains, nuts, and legumes in warm, humid regions—acts synergistically with hepatitis B infection to multiply cancer risk through specific TP53 mutations. Less common hereditary disorders, such as hereditary haemochromatosis (an iron overload disorder), alpha-1 antitrypsin deficiency, and Wilson's disease, also increase risk by inflicting continuous oxidative damage on hepatocytes. Protecting against HCC involves targeted interventions: universal infant vaccination against Hepatitis B, direct-acting antiviral therapies to eradicate Hepatitis C, alcohol cessation, and aggressive management of metabolic health through diet, exercise, and medical therapy.

The diagnostic pathway for hepatocellular carcinoma is distinctive because, in high-risk patients, a definitive diagnosis can often be established using high-resolution non-invasive imaging alone, without the absolute necessity of an invasive tissue biopsy. International clinical guidelines recommend that all individuals with established cirrhosis, as well as select non-cirrhotic patients with active chronic Hepatitis B, participate in regular surveillance programmes. This involves an abdominal ultrasound scan paired with a blood test measuring alpha-fetoprotein (AFP) conducted every six months. Ultrasound provides a safe, radiation-free assessment of the liver architecture, capable of detecting small, discrete nodules before they generate symptoms.

When a surveillance scan reveals a suspicious liver nodule measuring 1 centimetre or larger, the next step is multiphasic cross-sectional imaging, using either contrast-enhanced multiphase Computed Tomography (CT) or Dynamic Contrast-Enhanced Magnetic Resonance Imaging (MRI). These imaging protocols evaluate the vascular behaviour of the nodule across distinct circulatory phases: the late arterial phase, the portal venous phase, and the delayed 'washout' phase. Hepatocellular carcinoma has a unique vascular profile: normal liver tissue derives roughly 75% of its blood flow from the portal vein and 25% from the hepatic artery, whereas HCC tumours stimulate neo-angiogenesis, obtaining up to 90% of their blood supply from newly formed branches of the hepatic artery.

Consequently, on multiphasic imaging, a classic HCC demonstrates rapid, intense uptake of contrast during the arterial phase ('arterial hyperenhancement'), followed by rapid clearance of the contrast agent relative to the surrounding liver parenchyma during the venous and delayed phases ('washout'), often accompanied by the appearance of a enhancing peripheral pseudocapsule. If a nodule in a cirrhotic liver displays this quintessential radiological hallmark, established diagnostic criteria (such as the Liver Imaging Reporting and Data System, or LI-RADS) permit a formal cancer diagnosis without a biopsy. Tissue biopsies are reserved for indeterminate cases, instances where imaging findings are atypical, non-cirrhotic livers, or when specific molecular characterisation is required to guide targeted clinical trials.

Staging hepatocellular carcinoma is fundamentally distinct from the traditional TNM (Tumour, Node, Metastasis) framework used for most solid tumours. Because long-term outcomes and treatment safety depend equally on the extent of the cancer and the physiological stamina of the non-tumorous liver, oncology centres internationally rely on the Barcelona Clinic Liver Cancer (BCLC) staging system. The BCLC system categorises patients into five clinical stages (0, A, B, C, and D) by integrating three components: tumour characteristics (number, size, vascular invasion, and spread), baseline liver function, and the patient's overall physical functional performance status (measured by the ECOG score).

To rigorously assess the liver function component within the BCLC algorithm, clinicians utilise the Child-Pugh classification system. The Child-Pugh score grades liver functional reserve into three tiers: Class A (well-preserved function, 5-6 points), Class B (moderately compromised function, 7-9 points), and Class C (severe decompensation, 10-15 points). The score is calculated by evaluating five clinical parameters: serum bilirubin (measuring bile clearance), serum albumin (measuring protein synthesis), the international normalised ratio or INR (measuring blood coagulation capacity), and the physical presence and severity of ascites and hepatic encephalopathy.

Under the BCLC system, Stage 0 (Very Early) and Stage A (Early) represent single tumours or up to three nodules under 3 centimetres in patients with preserved Child-Pugh Class A or B function and excellent performance status; these patients are prime candidates for curative treatments. Stage B (Intermediate) reflects multinodular disease confined to the liver without vascular invasion, typically treated with locoregional therapies. Stage C (Advanced) involves tumours that have invaded the portal vein system or spread to distant sites like the lungs or bones, or those causing mild performance limitations, requiring systemic medical therapies. Finally, Stage D (End-Stage) comprises patients with severe Child-Pugh Class C liver failure, regardless of tumour size, where supportive palliative care is recommended unless liver transplantation is feasible.

Biomarker testing provides essential diagnostic, prognostic, and therapeutic information throughout the management of hepatocellular carcinoma. The most widely established serum biomarker is alpha-fetoprotein (AFP). AFP is an oncofoetal glycoprotein normally produced by the developing foetus; its production drops dramatically shortly after birth. In adults, elevated serum AFP levels can indicate hepatocyte regeneration, but significantly elevated or rising concentrations strongly suggest the presence of HCC. While AFP alone is insufficiently sensitive to diagnose small tumours—as roughly 30% to 40% of early-stage HCC tumours do not secrete elevated AFP—monitoring trends over time is invaluable for evaluating treatment response and monitoring for cancer recurrence.

To enhance biomarker sensitivity, specialised centres may analyse an expanded panel of serological markers alongside total AFP. These include AFP-L3 (a specific glycoform of AFP that exhibits high specificity for malignant liver cells) and Des-gamma-carboxy prothrombin (DCP), also known as prothrombin induced by vitamin K absence-II (PIVKA-II). When combined with patient age and sex in mathematically validated algorithms, such as the GALAD score, these circulating biomarkers help estimate the likelihood of malignancy even when cross-sectional imaging reveals borderline or ambiguous findings.

At present, routine genomic profiling or next-generation sequencing (NGS) of tumour tissue is not uniformly required for initial frontline treatment selection in HCC, unlike in non-small cell lung or colorectal cancers. However, comprehensive genomic profiling is increasingly performed when standard therapies fail or within specialised clinical trials. Researchers analyse tissue biopsies and circulating cell-free tumour DNA ('liquid biopsies') for alterations in genes such as CTNNB1, TERT, and TP53, as well as microsatellite instability (MSI-H) and high tumour mutational burden (TMB-H). Identifying these rare genetic subsets can open avenues for targeted second-line treatments or tumour-agnostic immunotherapies.

Primary liver cancer encompasses several distinct histological subtypes, of which hepatocellular carcinoma is by far the most prevalent, accounting for roughly 75% to 85% of all primary hepatic malignancies. HCC arises directly from malignant hepatocytes. The second most common primary liver malignancy is intrahepatic cholangiocarcinoma (ICC), which accounts for approximately 10% to 15% of cases. Arising from the epithelial cells lining the bile ducts within the liver, cholangiocarcinoma behaves differently from HCC: it often develops in non-cirrhotic livers, displays distinct genetic mutations (such as FGFR2 fusions and IDH1 alterations), and requires different surgical and systemic treatment strategies.

Less common primary liver cancers include combined hepatocellular-cholangiocarcinoma (cHCC-CCA), a rare hybrid tumour displaying features of both hepatocyte and biliary differentiation, and fibrolamellar carcinoma, an uncommon variant of HCC that typically arises in adolescents and young adults without pre-existing liver disease or cirrhosis. Extremely rare types include angiosarcoma and hemangiosarcoma, aggressive malignancies originating within the blood vessels of the liver. Finally, it is crucial to differentiate primary liver cancers from secondary (metastatic) liver cancer, wherein tumours originate in distant organs—such as the bowel, breast, lung, or pancreas—and spread to the liver via the bloodstream. Metastatic cancers retain the biological characteristics of their primary origin and are treated according to those primary tumour protocols.

The selection of treatment for hepatocellular carcinoma is determined by the BCLC stage, the Child-Pugh score, and the patient's general health. For patients diagnosed at an early stage (BCLC 0 or A) with preserved liver function (Child-Pugh A), curative-intent treatments are the priority. Surgical resection (partial hepatectomy) involves removing the tumour along with a safe margin of healthy tissue. Resection is ideal for single tumours without invasion into blood vessels, provided the remaining liver volume is sufficient to prevent post-operative liver failure and there is no severe portal hypertension.

For patients who cannot undergo resection due to tumour location, anatomical constraints, or early portal hypertension, thermal ablation offers an alternative curative approach. Techniques such as radiofrequency ablation (RFA) and microwave ablation (MWA) utilise localised thermal energy delivered via image-guided needles inserted directly through the skin into the tumour. Ablation is particularly effective for small tumours under 3 centimetres, creating a zone of coagulative necrosis that destroys the malignant cells while sparing the surrounding liver tissue. When tumours are multiple or underlying cirrhosis is advanced, orthotopic liver transplantation represents a powerful option. Governed typically by the Milan Criteria (a single tumour up to 5 centimetres, or up to three tumours each 3 centimetres or less, without vascular invasion or spread), transplantation removes both the cancer and the diseased cirrhotic organ, addressing the tumour and eliminating the risk of future primary liver malignancies.

For intermediate-stage HCC (BCLC B), where tumours are widespread within the liver but organ function remains stable, locoregional catheter-directed interventions are standard. Transarterial chemoembolisation (TACE) exploits the tumour's arterial blood supply. An interventional radiologist navigates a catheter through the femoral or radial artery directly into the hepatic arterial branches supplying the tumour. Highly concentrated chemotherapy (such as doxorubicin or cisplatin) is delivered locally, followed by embolic particles that block blood flow, depriving the tumour of oxygen and entrapping the cytotoxic medicine inside. A related modality, transarterial radioembolisation (TARE) or selective internal radiation therapy (SIRT), delivers microscopic glass or resin beads loaded with radioactive Yttrium-90 directly into the tumour vasculature, delivering high-dose local radiotherapy.

For advanced-stage HCC (BCLC C) or disease progressing despite locoregional therapy, systemic therapy is indicated. The therapeutic landscape was transformed with the arrival of combination immunotherapy. The global standard frontline treatment pairs atezolizumab (an immune checkpoint inhibitor targeting PD-L1) with bevacizumab (a monoclonal antibody targeting VEGF, which inhibits new blood vessel formation). By unmasking the tumour to the immune system while normalising tumour vasculature, this combination has demonstrated superior survival compared to older drugs. Another validated frontline regimen combines the dual immunotherapies durvalumab and tremelimumab. For patients with contraindications to immunotherapy, oral tyrosine kinase inhibitors (TKIs) such as sorafenib or lenvatinib serve as effective first-line options, with cabozantinib and regorafenib available as second-line targeted agents upon progression.

Participation in clinical trials is a crucial consideration across all stages of liver cancer. Ongoing clinical research is actively investigating combinations of locoregional therapies with modern immunotherapies, novel cellular therapies (such as CAR-T cell infusions), and personalised neoantigen vaccines. Patients are encouraged to discuss clinical trial options with their medical oncologist, as early access to emerging compounds may offer therapeutic benefit while advancing scientific standards of care.

Survival outcomes in hepatocellular carcinoma are deeply tied to the stage at which the disease is diagnosed and the stability of the patient's baseline liver function. When HCC is detected early (BCLC Stage 0 or A) and patients are eligible for curative interventions—such as liver transplantation, complete surgical resection, or radiofrequency ablation—five-year survival rates can reach roughly 60% to 80%. Liver transplantation, in particular, achieves excellent long-term disease-free survival because it replaces the chronically diseased tissue that would otherwise remain at high risk of generating new primary tumours.

For patients with intermediate or advanced disease, prognosis has improved substantially due to advances in locoregional techniques and modern systemic therapies. Historically, median survival for untreated advanced HCC was approximately 6 to 8 months; however, modern combination regimens such as atezolizumab plus bevacizumab have extended median overall survival to approximately 19 to 24 months in clinical trial populations with preserved liver function. It is essential to remember that published survival statistics represent broad population averages from past trials; individual prognoses vary considerably based on age, performance status, viral load control, and ongoing preservation of Child-Pugh Class A liver function.